European Centre for Disease Prevention and Control, SE-171 83 Stockholm, Sweden.
Expert Rev Vaccines. 2010 Apr;9(4):371-80. doi: 10.1586/erv.10.20.
The success of vaccination programs is an uncontroversial reality--in Europe as well as worldwide. On the other hand, the perceived risk of adverse events in the general public is the most important threat for implementing successful vaccination programs in Europe. For this reason, monitoring and assessing vaccine safety is a priority for public health. Vaccine safety is assessed both before and after vaccine authorization. In postmarketing settings, different activities related to vaccine safety usually involve several different stakeholders. In 2005, a new EU agency, the European Centre for Disease Prevention and Control, was established with the aim to strengthen Europe's defences against infectious diseases. Implementing stable links between different stakeholders and defining clear roles in the EU is paramount in order to provide optimal and transparent information on adverse reactions following immunization, with the final goal of increasing compliance to safe and effective vaccination programs.
疫苗接种计划的成功是一个无可争议的事实——无论是在欧洲还是在全球范围内。另一方面，公众对不良事件的感知风险是在欧洲实施成功疫苗接种计划的最重要威胁。出于这个原因，监测和评估疫苗安全是公共卫生的首要任务。疫苗安全性在疫苗获得授权之前和之后都进行评估。在上市后环境中，与疫苗安全相关的不同活动通常涉及几个不同的利益相关者。2005 年，成立了一个新的欧盟机构，即欧洲疾病预防控制中心，旨在加强欧洲对传染病的防御能力。在欧盟内部建立不同利益相关者之间的稳定联系并明确界定角色至关重要，以便就免疫接种后的不良反应提供最佳和透明的信息，最终目标是提高对安全有效的疫苗接种计划的依从性。
